PANTAKURE Tablet

- Duodenal ulcer

- Gastric ulcer

- Moderate and severe forms of reflux oesophagitis

Dosage and administration

Unless otherwise prescribed, the following oral doses apply. Please follow these instructions otherwise there is a risk that the drug may not act properly.

For duodenal and gastric ulcer and reflux oesophagitis the recommended daily dose is 1 PANTAKUGE tablet.

In individual cases twice this dose (up to 2 tablets daily) can be administered to patients with reflux oesophagitis or gastric and duodenal ulcer, particularly if they have not responded to other drugs.

In elderly patients and patients with impaired renal function, the daily dose of 40mg should not be exceeded.

Type and duration of treatment

This tablets should not be chewed or crushed, and should be taken whole with liquid either before or during breakfast. A duodenal ulcer generally heals within 2 weeks.

Gastric ulcer and reflux oesophagitis usually require 4 weeks of treatment.

However in individual cases treatment for duodenal ulcer can be prolonged upto 4 weeks and treatment for gastric ulcer and reflux oesophagitis can be prolonged upto 8 weeks.

As experience with long term treatment is limited, therapy should not exceed 8 weeks.

In patients with known hypersensitivity to any component of the formulation.

Treatment with PANTAKURE can occasionally lead to headache or diarrhoea.

There were rare reports of nausea, upper abdominal pain, flatulence, skin rash, pruritus or dizziness.

Edema, fever, the onset cf depression and disturbances in vision (blurred vision) were reported in individual cases.

PANTAKURE is metabolized in the liver via the cytochrome P450 enzyme system. An interaction with other drugs which are metabolized using the same enzymes system cannot be excluded. No clinically significant interactions were, however, observed in specific test with a number of such drugs, namely diazepam, warfarin, theophylline, phenytoin, digoxin and an oral contraceptive.

There were also no interactions seen with concomitantly administered antacids.

PANTAKURE is a proton pump inhibitor (PPI) that suppresses the final step in gastric acid production by forming a covalent bond to two sites of the (H+,K+)-ATPase enzyme system at the secretory surface of gastric parietal cell. This effect is dose-related and leads to the inhibition of both basal and stimulated gastric acid secretion irrespective of the stimulus. The binding to the (H+,K+)-ATPase results in a duration of anti-secietory effect that persists longer than 24 hours.